Carvykti Disease Interactions
There are 4 disease interactions with Carvykti (ciltacabtagene autoleucel).
Ciltacabtagene autoleucel (applies to Carvykti) hepatic impairment
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease
Ciltacabtagene autoleucel has not been tested in patients with liver impairment. Caution and close monitoring are advised if used in these patients.
References
- (2022) "Product Information. Carvykti (ciltacabtagene autoleucel)." Janssen Biotech, Inc., 1
Ciltacabtagene autoleucel (applies to Carvykti) hepatitis reactivation
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Infectious Hepatitis
Treatment with ciltacabtagene autoleucel may cause hypogammaglobulinemia. Hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure and death, can occur in patients with hypogammaglobulinemia. Perform screening for cytomegalovirus (CMV), HBV, hepatitis C virus (HCV), and human immunodeficiency virus (HIV) or any other viral infectious agents in accordance with clinical guidelines before collection of cells for manufacturing and treatment with this agent. Consider antiviral therapy to prevent viral reactivation per local institutional guidelines and clinical practice.
References
- (2022) "Product Information. Carvykti (ciltacabtagene autoleucel)." Janssen Biotech, Inc., 1
Ciltacabtagene autoleucel (applies to Carvykti) infections
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral
Ciltacabtagene autoleucel should not be administered to patients with active infection or inflammatory disorders. Severe, life-threatening, or fatal infections have occurred in patients after infusion with this drug. Active infections should be treated before treatment initiation.
References
- (2022) "Product Information. Carvykti (ciltacabtagene autoleucel)." Janssen Biotech, Inc., 1
Ciltacabtagene autoleucel (applies to Carvykti) renal impairment
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction
Ciltacabtagene autoleucel has not been tested in patients with renal impairment. Caution and close monitoring are advised if used in these patients.
References
- (2022) "Product Information. Carvykti (ciltacabtagene autoleucel)." Janssen Biotech, Inc., 1
Carvykti drug interactions
There are 198 drug interactions with Carvykti (ciltacabtagene autoleucel).
More about Carvykti (ciltacabtagene autoleucel)
- Carvykti consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Latest FDA alerts (2)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous antineoplastics
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.